AI Stock Memo: CGEN - Compugen - RankAlpha

CGEN

Rating neutralAI Memo

Compugen

As of 2026-06-18/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-06-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

MAIA-ovarian interim analysis is the main valuation reset • 2027-03-31

Expected move: -11%

Biggest risk

The supported bear case is that there is still no near-term operating inflection: Q1 revenue was modest and tied to collaboration accounting, R&D spend increased with clinical activity, losses continued, and the core valuation reset still depends on a future ovarian trial interim analysis that could disappoint or slip [#PR-2026-05-18].

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The supported bull case is balance-sheet durability plus pipeline optionality: management said MAIA-ovarian enrollment is on track for a Q1 2027 interim look, AstraZeneca continues advancing rilvegostomig broadly, GS-0321 Phase 1 is progressing, and cash is expected to fund operations into 2029 [#PR-2026-05-18].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-06-18

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 2026 results kept the story in monitoring mode
Runway into 2029 lowers financing pressure while partnered assets advance
The supported bull case is balance-sheet durability plus pipeline optionality: management said MAIA-ovarian enrollment is on track for a Q1 2027 interim look, AstraZeneca continues advancing rilvegostomig broadly, GS-0321 Phase 1 is progressing, and cash is expected to fund operations into 2029 [#PR-2026-05-18].

BearKey bullets

Forward visibility is thin because coverage is low, verified analyst-revision evidence is sparse, and most near-term upside still depends on partner or trial execution rather than recurring operations.
MAIA-ovarian remains a binary clinical driver, and failure to show a meaningful progression-free-survival benefit at interim could pressure the equity materially.
Quarterly losses continued in Q1 2026 and R&D expense increased as the company funded MAIA-ovarian and drug supply, so cash burn still needs monitoring even with runway guidance into 2029 [#PR-2026-05-18].

WatchKey bullets

MAIA-ovarian interim analysis is the main valuation reset

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $2 (p=45%)

Bull/Bear spread: +36% / -53%

Vs latest close: Bull +36% · Base -11% · Bear -53%

Scenario probabilities

Bull Target: $3 (p=25%)Base Target: $2 (p=45%)Bear Target: $1 (p=30%)

Commentary

Primary-source support improved after confirming the May 18, 2026 Form 6-K and furnished company press release, which directly support the runway, spend, and Q1 2027 interim-timing claims [#SEC-6K-2026-05-18] [#PR-2026-05-18]. Even so, this remains a low-coverage small-cap biotech monitoring setup with limited verified post-print analyst reaction and no trustworthy primary-source evidence of a broader thesis change since the Q1 release.

As of 2026-06-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 2026 results kept the story in monitoring mode
Runway into 2029 lowers financing pressure while partnered assets advance

Scenarios

Bull Target (Scenario probability)

$3 / p=25% prob

Base Target (Scenario probability)

$2 / p=45% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Price $2 as of 2026-07-31

Nearest Scenario: Base (∆ 11%)

Targets vs latest close: Bull +36% · Base -11% · Bear -53%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-03-31
MAIA-ovarian interim analysis is the main valuation reset
The company said COM701 MAIA-ovarian is actively enrolling across the U.S., Israel, and France and remains on track to have median progression-free survival at the interim analysis by Q1 2027, making this the clearest binary catalyst for the stock [#PR-2026-05-18].
Prob 50.00% • Move 35.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

Q1 2026 results kept the story in monitoring mode
2026-05-18
Compugen's May 18, 2026 Form 6-K and attached Exhibit 99.1 showed roughly $2.2 million of Q1 revenue, R&D expense rising to about $6.9 million mainly from MAIA-ovarian and drug-supply costs, and net loss of about $7.7 million, which supports a cautious read rather than a near-term operating inflection [#SEC-6K-2026-05-18] [#PR-2026-05-18].
Prob 70% • Move 5% • Priced-in 80%

Long-term Catalysts

Months to a year

Runway into 2029 lowers financing pressure while partnered assets advance
2026-12-31
Compugen reported about $134.9 million in cash, cash equivalents, deposits, and marketable securities as of March 31, 2026, said that should fund operations into 2029 with no debt, and highlighted continued progress for AstraZeneca-partnered rilvegostomig and Gilead-partnered GS-0321; that extends time for pipeline execution but does not remove clinical risk [#PR-2026-05-18].
Prob 55% • Move 12% • Priced-in 50%

Risks

Forward visibility is thin because coverage is low, verified analyst-revision evidence is sparse, and most near-term upside still depends on partner or trial execution rather than recurring operations.
MAIA-ovarian remains a binary clinical driver, and failure to show a meaningful progression-free-survival benefit at interim could pressure the equity materially.
Quarterly losses continued in Q1 2026 and R&D expense increased as the company funded MAIA-ovarian and drug supply, so cash burn still needs monitoring even with runway guidance into 2029 [#PR-2026-05-18].
Reported revenue remains small and largely collaboration-related, limiting fundamental support if pipeline or partner milestones slow.

Peers

Symbol	Summary
IMUX	Loose small-cap clinical biotech peer useful mainly for framing financing durability and event-driven readout volatility rather than direct target overlap.
NKTX	Another loose clinical-stage immuno-oncology comp where pipeline timing and cash runway matter more than current revenue.
UNCY	Useful only as a small-cap development-stage biotech risk comp; operating similarity to Compugen's immuno-oncology pipeline is limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-06-18